A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma

Zhixiao Sun; Jian Sun; Hang Hu; Shuhua Han; Panpan Ma; Bingqing Zuo; Zheng Wang; Zhongxiang Liu

doi:10.1016/j.heliyon.2024.e30646

A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma

Heliyon. 2024 May 4;10(9):e30646. doi: 10.1016/j.heliyon.2024.e30646. eCollection 2024 May 15.

Authors

Zhixiao Sun^{1

2}, Jian Sun³, Hang Hu¹, Shuhua Han⁴, Panpan Ma⁵, Bingqing Zuo¹, Zheng Wang⁶, Zhongxiang Liu^{1

2}

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, China.
² Department of Central Laboratory, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, China.
³ Department of Cardiothoracic Surgery, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, China.
⁴ Department of Pulmonary and Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, China.
⁵ Department of Clinical Laboratory, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, China.
⁶ Department of Chronic Disease Medical Center, The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, China.

Abstract

Background: Lung adenocarcinoma is one of the leading causes of cancer-related deaths because of the lack of early specific clinical indicators. MicroRNAs (miRNAs) have become the focus in lung cancer diagnosis. Further studies are required to explore miRNA expression in the serum of lung adenocarcinoma patients and their correlation with therapy and analyse specific messenger RNA targets to improve the specificity and sensitivity of early diagnosis.

Methods: The Toray 3D-Gene miRNA array was used to compare the expression levels of various miRNAs in the sera of patients with lung adenocarcinoma and healthy volunteers. Highly expressed miRNAs were selected for further analysis. To verify the screening results, serum and pleural fluid samples were analysed using qRT-PCR. Serum levels of the miRNAs and their correlation with the clinical information of patients with lung adenocarcinoma were analysed. The functions of miRNAs were further analysed using the Kyoto Encyclopedia of Gene and Genomes and Gene Ontology databases.

Results: Microarray analysis identified 60 and 50 miRNAs with upregulated and downregulated expressions, respectively, in the serum of patients with lung adenocarcinoma compared to those in healthy individuals. Using qRT-qPCR to detection of miRNAs expression in the serum or pleural effusion of patients with early and advanced lung adenocarcinoma, we found that miR-4433a-3p could be used as a diagnostic marker and therapeutic evaluation indicator for lung adenocarcinoma. Serum of miR-4433a-3p levels significantly correlated with the clinical stage. miR-4433a-3p may be more suitable than other tumour markers for the early diagnosis and evaluation of therapeutic effects in lung adenocarcinoma. miR-4433a-3p may affect tumour growth and metastasis by acting on target genes (PIK3CD, UBE2J2, ICMT, PRDM16 and others) and regulating tumour-related signalling pathways (MAPK signal pathway, Ras signalling pathway and others).

Conclusion: miR-4433a-3p may serve as a biomarker for the early diagnosis of lung adenocarcinoma and monitoring of therapeutic effects.

Keywords: Biomarker; Early diagnosis; Lung adenocarcinoma; Treatment; microRNAs.